• Ionomycin Free Acid for Calcium-FAK Research

  2026-08-17

  Ionomycin free acid provides a controllable calcium ionophore pulse for connecting intracellular calcium dynamics with FAK stability, adhesion, and TNBC phenotypes. This workflow separates direct calcium effects from FAISL-dependent regulation and adapts the same reagent logic to oocyte activation studies without overstating the evidence.

• TH287: A Temporal Framework for MTH1 Research

  2026-08-17

  TH287 is a potent MTH1 inhibitor for investigating oxidative stress-induced DNA damage and cancer cell selective cytotoxicity. This article focuses on the underappreciated role of treatment timing, assay design, and evidence interpretation in TH287-based radiosensitization studies.

• Vernakalant for Recent-onset Atrial Fibrillation

  2026-08-16

  This post hoc analysis of ACT I and ACT IV evaluated vernakalant for rapid cardioversion of recent-onset atrial fibrillation in emergency and cardiac-care settings. The study found that intravenous treatment converted substantially more patients to sinus rhythm than placebo, with a median conversion time of 12 minutes and no observed torsade de pointes or ventricular fibrillation.

• Potassium Iodide in Translational Assay Workflows

  2026-08-15

  Potassium Iodide (KI) supports controlled studies of iodide availability, thyroid hormone synthesis, and radioactive iodine thyroid blocking. This guide turns the reagent into a practical research workflow while showing how the cascade-targeting logic of an MMP-2-responsive liposome study can inform assay design without overstating KI’s role in cancer immunotherapy.

• JHU-083: Glutaminase Workflows for Neuro Research

  2026-08-14

  JHU-083 provides a practical pharmacological entry point for testing glutaminase activity in cerebral CD11b cells, glutamate biology, and experimental cerebral malaria research. This workflow also shows how redox-focused assays from acute hepatotoxicity research can strengthen, but not replace, mechanistic validation in neurological disease models.

• SNS-032: From CDK Biology to Translational Strategy

  2026-08-14

  SNS-032 (BMS-387032) offers a mechanistically rich way to study CDK2, CDK7, and CDK9 convergence across cell-cycle regulation, transcriptional control, oncology, and host–pathogen biology. This thought-leadership perspective connects phosphorylation biomarkers, assay design, translational positioning, and the emerging relevance of CDK9-linked vesicular transport while clearly separating established evidence from testable hypotheses.

• FXR–KLF11 Signaling in Contrast-Induced AKI

  2026-08-13

  This study identifies an FXR–KLF11 transcriptional axis that protects against contrast-induced acute kidney injury by restraining JAK2/STAT3 signaling. Through mouse, HK-2 cell, transcriptomic, reporter, ChIP, and loss-of-function experiments, the authors connect nuclear-receptor activation with reduced tubular inflammation and apoptosis.

• IEM-1925 in Soman-Induced Status Epilepticus

  2026-08-13

  The 2026 NeuroToxicology study evaluates IEM-1925 in a rat model of soman-induced status epilepticus and identifies combined antiseizure, neuroprotective, and cognitive benefits. Its EEG, histopathology, and behavioral data support dual AMPA/NMDA receptor targeting as a strategy for limiting acute seizures and subsequent neurological injury, while remaining preclinical.

• GSK2606414 for PERK-Driven ER Stress Research

  2026-08-12

  GSK2606414 is a potent, selective PERK inhibitor for separating PERK-dependent signaling from broader unfolded protein response effects. This practical guide translates a TMAO-driven zebrafish NAFLD study into cell, tissue, and translational workflows with assay controls and troubleshooting strategies.

• Palmitic acid: Protocol and QC Guide

  2026-08-12

  Palmitic acid (SKU N2456) provides a characterized source of hexadecanoic acid for non-aqueous fatty-acid supplementation and research involving lipid metabolism, inflammation signaling, and protein palmitoylation. It is water-insoluble, should not be retained as a long-term solution, and requires solvent-matched controls and prompt use after reconstitution.

• Mianserin HCl: Clinical Efficacy and Plasma Levels

  2026-08-11

  The reference study provided an early integrated evaluation of mianserin hydrochloride by comparing antidepressant efficacy, adverse effects, and plasma concentrations with amitriptyline in depressed in-patients. Its main practical contribution was showing similar apparent therapeutic efficacy, fewer reported side effects, and no clear relationship between measured plasma mianserin and clinical improvement.

• MK-571: Decoding Receptor–Transporter Biology

  2026-08-11

  MK-571 (L-660,711) is more than a leukotriene antagonist: it can also expose how ABCC1-mediated transport shapes macrophage drug responses. This article develops a practical framework for separating receptor pharmacology from transporter biology in inflammation and chemotherapy assays.

• In Vitro Drug Response Metrics in Cancer

  2026-08-10

  Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that growth inhibition and cell death are related but not interchangeable drug-response outcomes. This framework helps researchers design time-resolved assays and interpret cancer cell proliferation inhibition, cytotoxicity, and apoptosis assay data more accurately.

• EZ Cap™ Cas9 mRNA (m1Ψ): Editing Precision

  2026-08-09

  A thought-leadership perspective on how Cas9 mRNA architecture, innate immune signaling, intracellular exposure, and nuclear export collectively shape CRISPR-Cas9 precision and translational readiness.

• Relative and Fractional Viability in Cancer Drug Testing

  2026-08-08

  Schwartz’s 2022 dissertation distinguishes relative viability from fractional viability, showing that these commonly interchangeable readouts capture different combinations of proliferative arrest and cell death. The framework supports more precise cancer drug-response experiments by pairing growth and killing measurements across time rather than relying on a single endpoint.

16623 records 1/1109 page Next 12345 下5页 Last page